chevron_leftBack
As of 20 June 2026, Sinew Pharma Inc. has a market cap of $87.81M USD, ranking #26474 globally and #1473 in Taiwan.
It ranks #2371 in the Healthcare sector, and #457 in the Biotechnology industry.
Key Stats
Market Cap
$87.81MUSD
2.78B TWD
Enterprise Value
$54.99MUSD
1.74B TWD
Revenue (TTM)
$1.49KUSD
47.0K TWD
EBITDA (TTM)
-$4.02MUSD
-127.14M TWD
Net Income (TTM)
-$3.91MUSD
-123.75M TWD
PS Ratio
59078.8
PB Ratio
2.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Kai-Min Chu
open_in_new
Employees
57
Founded
2014
Website
sinewpharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 4.2% | -14% | 7.5% | -3.2% | -19% | -19% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
6634
欣耀生醫股份有限公司
ISIN: TW0006634009
Shares Out.:
Shares Outstanding:
71.142M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
38.10 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6919
|
$5.46B
6K%
172.76B TWD
|
-
|
|
TWSE: 6949
|
$1.61B
2K%
50.93B TWD
|
-
|
|
TPEX: 6696
|
$1.08B
1K%
34.04B TWD
|
-
|
|
TWSE: 7827
|
$726.25M
727%
22.97B TWD
|
-
|
|
|
TPEX: 7827
|
$600.25M
584%
18.98B TWD
|
-
|
|
TPEX: 06891
|
$571.26M
551%
18.06B TWD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
208K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
182K%
|
19.0
|
|
EBR: ARGX
|
$47.43B
54K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.23B
50K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.27B
48K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$41.88B
48K%
33.71B CHF
|
37.2
|
chevron_leftBack